Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Down to $1.29

Adaptimmune Therapeutics plc (NASDAQ:ADAP) gapped down before the market opened on Friday . The stock had previously closed at $1.29, but opened at $1.20. Adaptimmune Therapeutics shares last traded at $1.28, with a volume of 1,112,463 shares traded.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on Adaptimmune Therapeutics in a research report on Friday, December 29th. They set a “hold” rating on the stock.

Adaptimmune Therapeutics Stock Performance

The business has a fifty day moving average price of $1.42 and a 200 day moving average price of $0.91. The company has a market capitalization of $1.15 billion, a PE ratio of -2.11 and a beta of 2.39.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its earnings results on Wednesday, March 6th. The biotechnology company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.12). The company had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $4.80 million. Adaptimmune Therapeutics had a negative net margin of 188.90% and a negative return on equity of 155.39%. Research analysts forecast that Adaptimmune Therapeutics plc will post -0.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Adaptimmune Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Twin Focus Capital Partners LLC acquired a new stake in Adaptimmune Therapeutics during the 4th quarter valued at approximately $44,000. GSA Capital Partners LLP acquired a new stake in Adaptimmune Therapeutics during the 4th quarter valued at approximately $403,000. Key Client Fiduciary Advisors LLC grew its position in shares of Adaptimmune Therapeutics by 6.4% in the 4th quarter. Key Client Fiduciary Advisors LLC now owns 336,620 shares of the biotechnology company’s stock worth $267,000 after acquiring an additional 20,295 shares in the last quarter. Harbor Capital Advisors Inc. grew its position in shares of Adaptimmune Therapeutics by 9.9% in the 4th quarter. Harbor Capital Advisors Inc. now owns 147,732 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 13,317 shares in the last quarter. Finally, Marquette Asset Management LLC acquired a new position in shares of Adaptimmune Therapeutics in the 3rd quarter worth approximately $77,000. Institutional investors and hedge funds own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.